InnoCan Pharma Corporation

InnoCan Pharma Corporation

Innocan Pharma is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”) with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. The Company’s operations and research and development activities are based in Israel.

Innocan Pharma’s business can be described as three distinct operating segments relating to the incorporation in products of CBD in their formulation: (i) the research and development of the treatment of Covid-19 (and other viruses causing lung inflammation as well as other central nervous system (CNS) diseases such as epilepsy and Alzheimer’s Disease) by using CBD loaded exosomes (“CLX”); (ii) the research and development of the use of CBD loaded liposomes to provide pain relief and treat epilepsy and other central nervous system disorders and other indications; and (iii) the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain.



10 Hamenofim Street Herzliya, Herzliya , Israel 4672561


972 543012842





CSE: INNO: Canadian Securities Exchange

Key Executives

Iris Bincovich CEO

CEO Direct

Have a question? Ask the CEO.

Coverage: Reports/Articles

Coming Soon:

Need More Info From The Company?